DCTH - Delcath Systems Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

78.76M

Cash

24.22M

Avg Qtr Burn

-5.71M

Short % of Float

4.88%

Insider Ownership

2.88%

Institutional Own.

13.07%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CHEMOSAT® Details Uveal melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.